@article{a6382ed2aca8468f8a33cdb84438e2fd,
title = "Global perspectives on the burden of episodic and chronic migraine",
author = "Buse, {Dawn C.} and Lipton, {Richard B.}",
note = "Funding Information: Richard B. Lipton, MD, has received research support from the National Institutes of Health (NIH) (PO1 AG03949 (program director), PO1AG027734 (project leader), RO1AG025119 (investigator), RO1AG022374-06A2 (investigator), RO1AG034119 (investigator), RO1AG12101 (investigator), K23AG030857 (mentor), and K23NS05140901A1 (mentor), and K23NS47256 (mentor)); the National Headache Foundation and the Migraine Research Fund; serves on the editorial board of Neurology ; has reviewed for the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke (NINDS); holds stock options in eNeura Therapeutics (a company without commercial products in the US); and serves as consultant, advisory board member, or has received honoraria from: Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, CogniMed, Colucid, Eli Lilly, Endo, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, and Pfizer. Funding Information: Dawn C. Buse, PhD, has received honoraria and/or research funding from Allergan Pharmaceuticals, Merck Inc, MAP Pharmaceuticals, NuPathe, and Novartis. ",
year = "2013",
month = aug,
doi = "10.1177/0333102413477736",
language = "English (US)",
volume = "33",
pages = "885--890",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "11",
}